Marketing the latest imported Iressa price, imported Iressa price agency

r Beijing Iressa price in India imported Iressa price in India Price agent in India Iressa price New version of Iressa price in India
, r Our company promises: Integrity, genuine products, conscientious medicines, cash on delivery
Consultation hotline: < bb br )< bb br )
, r Manager Liu:
, r Beijing Chengxin Pharmaceutical:
Selling Indian Iressa: Indian Gleevec:
< r < Indian Iressa (gefitinib, English name b br) is a new type of small molecular weight tumor treatment drug. Its mechanism of action is mainly to block conduction by inhibiting R autophosphorylation and inhibit the proliferation of tumor cells. , to achieve targeted therapy. Clinically, it is mainly used to treat locally advanced or metastatic non-small cell lung cancer that has received chemotherapy in the past. It is especially effective for lung adenocarcinoma. The efficacy for squamous cell carcinoma is lower than that for adenocarcinoma and alveolar cancer. However, a large amount of clinical data shows that: according to The actual situation of lung cancer patients: After treatment with Iressa (gefitinib), some patients with lung squamous cell carcinoma and other non-small cell lung cancer still have obvious effects and are well tolerated.


, r Functions and Indications
This product is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer that has previously received chemotherapy. Previous chemotherapy treatments mainly referred to platinum and docetaxel treatments. The efficacy for patients with locally advanced or metastatic non-small cell lung cancer who have failed chemotherapy is established based on objective response rate indicators. There are no controlled studies showing clinical benefit in improving disease-related symptoms and extending survival. The existing data on the use of this product in the second-line treatment of non-small cell lung cancer are only based on uncontrolled clinical studies and need to be further confirmed by well-designed controlled clinical trials. For the first-line treatment of non-small cell lung cancer, the results of two large randomized controlled clinical trials showed that platinum-based dual chemotherapy regimens did not show any benefit after combined treatment with this product. Therefore, gefitinib is not suitable for this treatment. .